Print page Share page

About ARIAD's investigator-sponsored trials.

ARIAD supports independent research aimed at advancing clinical and scientific understanding of our products. All proposals submitted to ARIAD undergo scrutiny by a team of professionals for scientific merit and alignment with our research goals. If you are interested in submitting a research proposal, please contact us at IST@ariad.com.

Ponatinib is being studied in several investigator sponsored trials. Patient enrollment in all clinical studies of ponatinib is on temporary clinical hold.

Phase 2 Study of Ponatinib and Hyper-CVAD in Ph+ and/or BCR-ABL Positive ALL

Study Design: Non-randomized, open-label, single-center
Patients: Patients with Ph+ ALL and/or BCR-ABL positive ALL who were previously untreated or who previously received 1–2 courses of chemotherapy with or without other TKIs
Purpose: To learn if intensive chemotherapy combined with ponatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied.
Location: MD Anderson Cancer Center, Houston, TX

Phase 2 Study of Ponatinib in Newly Diagnosed CML Patients

Study Design: Non-randomized, open-label, single-center
Patients: Treatment-naïve patients diagnosed with CML within six months prior to enrollment
Purpose: To learn if ponatinib as initial therapy can help control CML in chronic phase. The safety of ponatinib in this setting will also be studied.
Location: MD Anderson Cancer Center, Houston, TX

Phase 2 Study of Ponatinib as Second Line Therapy in CML Patients Resistant or Intolerant to Imatinib

Study Design: Non-randomized, open-label, single-center
Patients: Patients with chronic phase CML who have demonstrated failure to therapy to imatinib
Purpose: To assess ponatinib following prior therapy with imatinib by evaluating major cytogenetic response (MCyR)
Location: MD Anderson Cancer Center, Houston, TX

Phase 2 Study of Ponatinib in Non-Small Cell Lung Cancer

Study Design: Non-randomized, open-label, single-center
Patients: Patients with lung squamous cell cancer (SCC) with an alteration in FGFR kinase
Purpose: To evaluate ponatinib as an FGFR inhibitor in patients with squamous cell lung cancer
Location: Dana Farber Cancer Institute, Boston, MA

Phase 2 Study of Ponatinib in Advanced Non-Small Cell Lung Cancer with RET Translocations

Study Design: Non-randomized, open-label, multi-center
Patients: Patients with advanced non-small cell lung cancer (NSCLC) with a RET translocation
Purpose: To evaluate ponatinib as a RET inhibitor in patients with NSCLC
Location: Massachusetts General Hospital, Boston, MA; City of Hope, Duarte, CA; University of California, Irvine, CA; Smilow Cancer Hospital at Yale, New Haven, CT; Ohio State University, Columbus, OH

Phase 2 Study of Ponatinib in Advanced Medullary Thyroid Cancer

Open for enrollment
Study Design: Non-randomized, open-label, single-center
Patients: Patients with localized or metastatic unresectable medullary thyroid cancer
Purpose: To determine the objective overall response rate of patients with MTC to ponatinib
Location: National Cancer Institute, Bethesda, Maryland

Phase 2 Study of Ponatinib with Cytarabine as Consolidation Therapy in Patients with FLT3-ITD AML

Not yet open for enrollment
Study Design: Non-randomized, open-label, multi-center, dose-escalation phase 1–2 trial
Patients: Patients with FLT3-ITD AML in first complete remission
Purpose: To assess the safety and efficacy of ponatinib in combination with high- or intermediate-dose cytarabine as consolidation therapy for patients with intermediate-risk cytogenetic FLT3-ITD AML
Locations: Hôpitaux de Versailles, Hôpital Mignot, France; approximately 45 ALFA and GOELAM clinical centers

Phase 2 Study of Ponatinib in FLT3-ITD AML Relapsed or Refractory After Standard Chemotherapy

Not yet open for enrollment
Study Design: Non-randomized, open-label, single-center
Patients: Patients with FLT3-ITD+ AML relapsed after or refractory to at least two standard chemotherapy regimens or unfit for chemotherapy
Purpose: To assess the safety and efficacy of ponatinib in relapsed or refractory FLT3-ITD+ AML with a view to achieving remission and bridging patients to allogeneic hematopoietic stem cell transplantation
Location: Queen Mary Hospital, Hong Kong

Phase 3 Study to Evaluate the Impact of Switching CML Patients Treated with a First-line Tyrosine Kinase Inhibitor to Ponatinib – SPIRIT 3

Not yet open for enrollment
Study Design: Randomized, open-label, multicenter
Patients: Adult patients with chronic-phase CML diagnosed within three months and previously untreated for CML with any TKI therapy
Purpose: To compare the efficacy and cost-effectiveness of front-line treatment of imatinib versus nilotinib in chronic myeloid leukemia (CML) with switching to ponatinib upon suboptimal response or treatment failure
Locations: Multiple sites throughout the U.K.

Investigator-sponsored trials

View all open clinical trials at ClinicalTrials.gov.

More
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue